(ERYP) – StreetInsider.com Reports
-
ERYTECH Pharma S.A. (ERYP) reports Q3 results
-
ERYTECH (ERYP) Receives Nasdaq Non-compliance Notice
-
ERYTECH (ERYP) No Longer Seeking Approval for Graspa in ALL
-
Pre-Open Stock Movers 04/25: PS Business Parks and Twitter Jump on Deal News; Axsome Sinks on Expected CRL (more...)
-
ERYTECH (ERYP) Sells US Manufacturing Facility; Enters Long-Term Supply Agreement with Catalent
-
ERYTECH (ERYP) Reports Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology
-
ERYTECH (ERYP) Announces 769K Direct Offering at $10.20/sh
-
Pre-Open Stock Movers 11/30: (CPIX) (IMGN) (VIR) Higher; (JKS) (LIZI) (SEDG) Lower (more...)
-
After-Hours Movers 11/29: (CPIX) (ADAG) (OM) Higher; (LIZI) (INTU) Lower (more...)
-
ERYTECH (ERYP) Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
-
Cowen Downgrades ERYTECH Pharma SA. (ERYP) to Market Perform
-
JMP Securities Downgrades ERYTECH Pharma SA. (ERYP) to Market Perform, Following Clinical Business Updae
-
ERYTECH's (ERYP) TRYbeCA-1 Phase 3 Trial Did Not Meet Primary Endpoint
-
ERYTECH (ERYP) Halted on LUDP, Up 107%
-
Pre-Open Movers 07/30: (ERYP) (TEAM) (MSON) Higher; (PINS) (ZYXI) (AMZN) Lower (more...)
-
After-Hours Stock Movers 07/29: (ERYP) (TEAM) (MSON) Higher; (PINS) (ZYXI) (AMZN) Lower (more...)
-
ERYTECH (ERYP) More than Doubles as FDA Grants Fast Track Designation for Eryaspase in Hypersensitive ALL
-
ERYTECH (ERYP) Sells $30M in Stock in Direct Offering at $7.25/ADS w/Warrants (Earlier)
-
ERYTECH (ERYP) Reports TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis
-
ERYTECH (ERYP) Reports First Patient Enrolled in Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
-
ERYTECH (ERYP) Reports Complete Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
-
ERYTECH (ERYP) Reports Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblastic Leukemia
-
ERYTECH (ERYP) Announces Update on TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer
-
ERYTECH (ERYP) Names Dr. Melanie Rolli to Board
-
ERYTECH (ERYP) Reports Publication of Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer
-
ERYTECH (ERYP) Reports Milestone Achievements in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer
-
JMP Securities Resumes ERYTECH Pharma SA. (ERYP) at Market Outperform
-
ERYTECH (ERYP) Reports First Patient Enrollement in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC
-
ERYTECH (ERYP) Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies
-
ERYTECH (ERYP) Announces FDA's Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer
-
ERYTECH (ERYP) Presents New Erymethionase Preclinical Findings at AACR
-
Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018
-
ERYTECH (ERYP) Reports First Enrollment of atients in Phase 3 Clinical Trial Evaluating Eryaspase for Treatment of Second Line Pancreatic Cancer
-
ERYTECH Pharma SA. (ERYP) PT Lowered to $33 at JMP Securities
-
ERYTECH (ERYP) Announces Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia
-
Cowen Starts ERYTECH Pharma SA. (ERYP) at Outperform
-
JMP Securities Starts ERYTECH Pharma SA. (ERYP) at Market Outperform
-
ERYTECH Pharma (ERYP) IPO Opens 15% Higher
Back to ERYP Stock Lookup